{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.8","upperLimit":"8","value":"6.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"Overall survival was defined as the duration between the date of enrollment and the date of death due to any cause. Patients last known to be alive were censored at the date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Daily oral Everolimus 10 mg/day\n\neverolimus","id":"OG000","title":"Everolimus"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Every 8 weeks until disease progression, up to 3 years.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}